Diffuse Large B-Cell Lymphoma News

News

Selinexor Associated With Increased OS in R/R DLBCL

12/02/2021

An investigative analysis in a subgroup of patients with R/R DLBCL from the SADAL study found increased OS associated with selinexor.

An investigative analysis in a...

12/02/2021

Oncology

News

Polatuzumab Vedotin Plus Bendamustine and Rituximab Shows Safety in R/R DLBCL

12/02/2021

Data from a phase 2 study of polatuzumab vedotin plus bendamustine and rituximab found the combination to be efficacious and safe for patients with R/R DLBCL.

Data from a phase 2 study of...

12/02/2021

Oncology

News

BTK, STAT3 Targeting Is Safe in R/R DLBCL, But Has Limited Efficacy

11/15/2021

A phase 1b study found acalabrutinib, plus AZD9150 is safe and tolerable for patients with R/R DLBCL, but has limited efficacy; these findings were presented at the 2021 ASH Annual Meeting.

A phase 1b study found...

11/15/2021

Oncology

Conference Insider

Tafasitamab With or Without Lenalidomide and R-CHOP Tolerable for Patients With DLBCL

11/11/2021

A phase 1B study shared at the 2021 Annual ASH Meeting reported on the safety and tolerability of tafasitamab in newly diagnosed DLBCL.

A phase 1B study shared at the...

11/11/2021

Oncology

News

Glofitamab Plus R-CHOP Induces High Response Rates in NHL, DLBCL

11/08/2021

Findings from a phase 1b study found glofitamab plus R-CHOP induces high response rates with minimal CRS in patients with R/R NHL and previously untreated DLBCL. These data were presented at the 2021 ASH Annual Meeting.

Findings from a phase 1b study...

11/08/2021

Oncology

News

SNPs Do Not Impact Outcomes With Ritixumab/Obinutuzumab in FL, DLBCL

08/16/2021

SNPs have been shown to influence FcγR activity in patients with FL and DLBCL, but do not impact treatment outcomes with rituximab/obinutuzumab plus chemo, study findings suggest.

SNPs have been shown to...

08/16/2021

Oncology

News

FDA Approves Loncastuximab Tesirine-lpyl for Patients With DLBCL

04/26/2021

The FDA has approved loncastuximab tesirine-lpyl for patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.

The FDA has approved...

04/26/2021

Oncology

News

ROBUST Study: R-CHOP With or Without Lenalidomide in ABC-Type DLBCL

04/19/2021

Adding lenalidomide to R-CHOP has been shown to improve outcomes in patients with DLBCL and activated B-cell-like disease.

Adding lenalidomide to R-CHOP...

04/19/2021

Oncology

Conference Insider

Long-Lasting Remission With Dual Targeting CAR-T Therapy for R/R DLBCL

12/15/2020

Patients with relapsed/refractory DLBCL given AUTO3 (a CD19/22 dual targeting CAR-T therapy) plus pembrolizumab had durable responses.

Patients with...

12/15/2020

Oncology

Conference Insider

Mosunetuzumab Safe, Effective for Elderly Patients With DLBCL

12/07/2020

Single-agent mosunetuzumab shows efficacy, remarkable safety, as a chemo-free option for previously untreated elderly/unfit patients with DLBCL.

Single-agent mosunetuzumab shows...

12/07/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology